NZ601780A - Amino Acid Prodrugs - Google Patents

Amino Acid Prodrugs

Info

Publication number
NZ601780A
NZ601780A NZ601780A NZ60178004A NZ601780A NZ 601780 A NZ601780 A NZ 601780A NZ 601780 A NZ601780 A NZ 601780A NZ 60178004 A NZ60178004 A NZ 60178004A NZ 601780 A NZ601780 A NZ 601780A
Authority
NZ
New Zealand
Prior art keywords
drug
amino acid
acid prodrugs
djk
dcy
Prior art date
Application number
NZ601780A
Other languages
English (en)
Inventor
V Chandran
Original Assignee
Signature R & D Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature R & D Holdings Llc filed Critical Signature R & D Holdings Llc
Publication of NZ601780A publication Critical patent/NZ601780A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ601780A 2003-07-29 2004-07-29 Amino Acid Prodrugs NZ601780A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49133103P 2003-07-29 2003-07-29

Publications (1)

Publication Number Publication Date
NZ601780A true NZ601780A (en) 2012-10-26

Family

ID=34590076

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ601772A NZ601772A (en) 2003-07-29 2004-07-29 Amino Acid Prodrugs
NZ601780A NZ601780A (en) 2003-07-29 2004-07-29 Amino Acid Prodrugs
NZ545570A NZ545570A (en) 2003-07-29 2004-07-29 Amino acid prodrugs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ601772A NZ601772A (en) 2003-07-29 2004-07-29 Amino Acid Prodrugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ545570A NZ545570A (en) 2003-07-29 2004-07-29 Amino acid prodrugs

Country Status (11)

Country Link
EP (1) EP1660017A4 (xx)
JP (2) JP2007510621A (xx)
KR (3) KR20130081319A (xx)
CN (1) CN101123878A (xx)
AU (1) AU2004289174B2 (xx)
CA (1) CA2534342C (xx)
IL (1) IL173382A0 (xx)
NZ (3) NZ601772A (xx)
SG (2) SG145693A1 (xx)
WO (1) WO2005046575A2 (xx)
ZA (1) ZA200600660B (xx)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
NZ601772A (en) * 2003-07-29 2012-10-26 Signature R & D Holdings Llc Amino Acid Prodrugs
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
CZ2006427A3 (cs) 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
CA2750725C (en) * 2004-01-07 2014-10-21 Seikagaku Corporation Spacer derivative for hyaluronic acid and non-steroidal anti-inflammatory drug residues
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
CA2607020C (en) * 2005-05-05 2015-01-13 Chroma Therapeutics Ltd. Alpha amino acid ester-drug conjugates hydrolysable by carboxylesterases
ZA200803933B (en) * 2005-11-11 2009-10-28 Chandran V Ravi Acetylated amino acids a anti-platelet agents, nutritional and vitamin supplements
KR101381768B1 (ko) 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
ES2643602T3 (es) 2006-03-31 2017-11-23 Sunovion Pharmaceuticals Inc. Aminas y quirales
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008005572A2 (en) * 2006-07-06 2008-01-10 Cytovia, Inc. Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
CN1907954B (zh) * 2006-08-16 2011-11-23 重庆医科大学医药研究所 麻醉药2,6-二异丙基苯酚的水溶性衍生物及其制备方法
WO2008053131A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CN103936605B (zh) 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
WO2008157537A2 (en) * 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
WO2009106844A1 (en) 2008-02-29 2009-09-03 Chroma Therapeutics Ltd. Inhibitors of p38 map kinase
TWI503101B (zh) * 2008-12-15 2015-10-11 Proteus Digital Health Inc 與身體有關的接收器及其方法
KR20110082601A (ko) 2008-12-19 2011-07-19 피너클 파마수티칼스, 인코포레이티드 페나조피리딘 화합물
AU2010264703A1 (en) * 2009-06-24 2012-02-02 Shire Llc Mexiletine amino acid and peptide prodrugs and uses thereof
NZ600430A (en) 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
CN101906039B (zh) * 2010-06-23 2013-05-08 四川大学华西医院 取代苯酚的羟基酸酯化合物、制备方法及在药物中的应用
MX2010011006A (es) 2010-10-06 2012-04-18 Senosiain S A De C V Lab Nueva sal de un derivado de pirimidina.
NZ611866A (en) 2010-11-12 2015-04-24 Univ Michigan Spiro-oxindole mdm2 antagonists
US20120196933A1 (en) * 2010-12-23 2012-08-02 Richard Franklin Mexiletine prodrugs
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
FR2976944A1 (fr) 2011-06-21 2012-12-28 Centre Nat Rech Scient Prodrogues peptidiques
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9809557B2 (en) 2011-10-31 2017-11-07 Claus Selch Larsen Prodrugs of non-steroid anti-inflammatory agents (NSAIDS)
AU2013202982C1 (en) 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
KR102443057B1 (ko) * 2012-01-18 2022-09-14 테크필즈 파마 코., 엘티디. 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
AU2013257745A1 (en) * 2012-05-07 2014-11-27 Cellixbio Private Limited Prodrugs of anti-platelet agents
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
TWI601725B (zh) * 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER
CN102924398B (zh) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 用于除去依非韦伦对应异构体的方法
CN103880754A (zh) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 一种丙泊酚碱性氨基酸酯盐
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
CN103263405B (zh) * 2013-05-08 2015-04-22 南京医科大学 用于治疗糖尿病的药物组合物及其应用
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
CN103360240B (zh) * 2013-07-23 2015-03-11 西安新通药物研究有限公司 一种高纯度非诺贝酸的制备方法
CN110098914B (zh) 2013-09-20 2021-10-29 大冢制药株式会社 接收和解码信号的方法、器件和系统
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
LT3116486T (lt) 2014-03-14 2020-04-10 Biomolecular Holdings Llc Hibridinis imunoglobulinas, turintis nepetidilinę jungtį
CN103951557B (zh) * 2014-04-22 2016-06-08 徐州工业职业技术学院 一种以无机碱为催化剂制备非诺贝特酸的方法
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
AU2014407862B2 (en) 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
CN104628554A (zh) * 2015-02-09 2015-05-20 徐州工程学院 一种非诺贝特酸晶型及其制备方法
CN106146444A (zh) * 2015-04-03 2016-11-23 米文君 一种新的化合物及其用途
CN105037180B (zh) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
MY189759A (en) * 2016-03-18 2022-03-02 Caregen Co Ltd Conjugate of finasteride with peptide
CN107949566B (zh) * 2016-05-10 2021-09-28 浙江海正药业股份有限公司 水溶性雷帕霉素类衍生物
CN106316921B (zh) * 2016-08-19 2019-03-29 河南东泰制药有限公司 一种阿西美辛的制备方法
CN108948140B (zh) * 2017-05-18 2021-10-26 首都医科大学 华法林-4-O-乙酰-Arg-AA十一种化合物,其合成,活性和应用
CN108948139B (zh) * 2017-05-18 2021-10-26 首都医科大学 华法林-4-O-乙酰-Arg-AA化合物,其合成,活性和应用
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN108299219A (zh) * 2018-02-11 2018-07-20 中国农业大学 O-酰基化丝氨酸衍生物及其制备方法与应用
RS64436B1 (sr) 2018-09-14 2023-09-29 Enlitisa Shanghai Pharmaceutical Co Ltd Konjugati montelukasta i peptida
CN116041259A (zh) * 2023-01-13 2023-05-02 武汉科技大学 一种羟氯喹的衍生物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
WO1992021341A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
JPH1143467A (ja) * 1997-05-14 1999-02-16 Ikeda Mohandou:Kk 脂肪酸グリセライド誘導体及びグリセライド誘導体、並びにそれらの製造方法
IT1294205B1 (it) * 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
AU8494601A (en) * 2000-08-18 2002-03-04 Univ Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
EP1605946B1 (en) * 2003-03-25 2008-05-28 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
NZ601772A (en) * 2003-07-29 2012-10-26 Signature R & D Holdings Llc Amino Acid Prodrugs

Also Published As

Publication number Publication date
CA2534342C (en) 2016-05-10
AU2004289174B2 (en) 2011-05-19
KR20120116991A (ko) 2012-10-23
IL173382A0 (en) 2006-06-11
JP2007510621A (ja) 2007-04-26
AU2004289174A2 (en) 2005-05-26
KR20130081319A (ko) 2013-07-16
NZ601772A (en) 2012-10-26
EP1660017A2 (en) 2006-05-31
NZ545570A (en) 2012-07-27
EP1660017A4 (en) 2011-03-09
CN101123878A (zh) 2008-02-13
WO2005046575A3 (en) 2007-10-04
SG178721A1 (en) 2012-03-29
SG145693A1 (en) 2008-09-29
ZA200600660B (en) 2007-04-25
KR20060073584A (ko) 2006-06-28
WO2005046575A2 (en) 2005-05-26
CA2534342A1 (en) 2005-05-26
AU2004289174A1 (en) 2005-05-26
JP2013035863A (ja) 2013-02-21

Similar Documents

Publication Publication Date Title
NZ601780A (en) Amino Acid Prodrugs
WO2006119170A3 (en) Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
WO2007104738A3 (en) Acylated single chain insulin
WO2009092071A3 (en) Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
WO2008089491A3 (en) Modifications of peptide compositions to increase stability and delivery efficiency
EP2455462A3 (en) Lipase variants for pharmaceutical use
MX2008001711A (es) Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa.
WO2009087082A3 (de) Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
WO2008075371A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
WO2004103390A3 (en) Stable analogs of peptide and polypeptide therapeutics
WO2007067495A3 (en) Levodopa prodrug mesylate, compositions thereof, and uses thereof
UA86622C2 (ru) Фармацевтическая композиция, которая диспергируется в ротовой полости, для введения в слизистую оболочку ротовой полости или подъязычного введения агомелатина
WO2005074970A3 (en) Neuroprotective dietary supplement
EP1644504B8 (en) Factor vii or viia gla domain variants
CA2651990C (en) Improved antimicrobial peptides
WO2006112717A3 (en) Nutritional supplement for a category of hiv patients
IL159960A (en) Indane acetic acid derivatives, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments
EP1897550A3 (en) Prodrugs of Excitatory Amino Acids
MX2012007416A (es) Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis.
RU2012121562A (ru) Комбинация для лечения мукозита, индуцированного облучением или химиотерапией
WO2008066816A3 (en) Derivatization or ligaton of peptides
ATE541581T1 (de) Medikament für die krebstherapie
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 29 JUL 2014 BY PIPERS

Effective date: 20130426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 JUL 2017 BY COMPUTER PACKAGES INC

Effective date: 20140729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2018 BY COMPUTER PACKAGES INC

Effective date: 20170801

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2019 BY COMPUTER PACKAGES INC

Effective date: 20180703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JUL 2020 BY COMPUTER PACKAGES INC

Effective date: 20190718

LAPS Patent lapsed